N/A N=374 Operations and Pelvic Muscle Training in the Management of Apical Support Loss: The OPTIMAL Trial
Pelvic Organ Prolapse (POP)
Primary: Surgical Success — 25; 30; 28; 27 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction
Meibomian Gland Dysfunction
Primary: Meibomian Gland Secretion Appearance at Visit 4 (Day 168) — 0.80; 0.96 units on a scale
N/A N=236 Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting
Hemostasis · Bleeding
Primary: The Time to Hemostasis Measured From Start of Study Treatment to the Achievement of Hemostasis at the Target Bleeding Site (TBS), or to the End of the 10-minute…
N/A N=216 A Study to Evaluate the Product Feasibility of Two New Silicone Hydrogel Contact Lenses
Myopia
Primary: Visual Acuity — -0.089; -0.087; -0.086; -0.086 logMAR
Phase 2 N=59 A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)
Refractory Chronic Cough
Primary: Change in Awake Objective Cough Frequency on Log-transformed Scale - Cohort 1 — 0.56; 0.95; 0.46; 0.95 Log coughs/hour — p=0.0055
Phase 3 N=312 This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
Heart Failure
Primary: Change From Baseline to Week 12 in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance — 18.0; 13.5 Meter (m) — p=0.4236
N/A N=38 Microenterprise Intervention to Reduce Sexual Risk Behaviors in Young Adults
Feasibility
Primary: Proportion of Participants in Both Groups Who Have Responded to 70% or More of the Weekly Text Message Surveys — 5; 9 Participants
N/A N=48 Quincy Family, Youth & Technology For Lifestyle Change (FYT-4-LIFE) Study
Pediatric Obesity
Primary: Parent/Guardian Knowledge of Healthy Family Routines and of Parenting Strategies That Are Preventive of Child Overweight and Obesity — 1.2; 0.9 units on a scale
N/A N=170 Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions
Arthritis, Rheumatoid
Primary: Change From Baseline in Routine Assessment of Patient Index Data 3 (RAPID3) Score at Month 6 — 7.12; 5.95; 5.88; 5.94 units on a scale
N/A N=18 Development of An Exergame for Caregivers of Individuals With Alzheimer's Disease or Related Dementias
Sedentary Lifestyle · Stress, Psychological
Primary: Number of Steps — 8857; 8179; 8659; 7867 Daily Steps — p=.0008
Phase 1 N=9 NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Malignant Melanoma
Primary: Number of Patients With Treatment-emergent Adverse Events (TEAEs) — 8; 8; 0; 0 Participants
Phase 4 N=45 Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
Type2 Diabetes · Cardiovascular Diseases
Primary: Changes in Measure of Heart Rate Variability Using Dapagliflozin vs Active Comparator Glimepiride. — -0.18; -0.34; 0.26; 0.26 LF:HF ratio — p=0.28
Phase 3 N=24 Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies
Pancreatic Cancer · Unresectable Biliary-pancreatic Malignancies
Primary: Rate of Failure
Phase 2 N=24 Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion
Diabetes Mellitus Type 2
Primary: Total and First Phase of Insulin Secretion (Insulinogenic Index and Stumvoll Index) After 90 Days — 0.41; 0.23; 1135.7; 309.0 index
N/A N=54 Behavioral Intervention in Reducing Indoor Tanning
Healthy Subject
Primary: Number of Prior 2-Month Indoor Tanning Sessions Reported by Participants on a Follow-up Survey — 11.5; 7.9 indoor tanning sessions